JP2013509433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509433A5 JP2013509433A5 JP2012537128A JP2012537128A JP2013509433A5 JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5 JP 2012537128 A JP2012537128 A JP 2012537128A JP 2012537128 A JP2012537128 A JP 2012537128A JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- compound
- pharmaceutically acceptable
- acceptable salt
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000036142 Viral infection Diseases 0.000 claims 9
- 230000009385 viral infection Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 6
- 241000701460 JC polyomavirus Species 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 6
- 241000701022 Cytomegalovirus Species 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 4
- 241000701027 Human herpesvirus 6 Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 241000829111 Human polyomavirus 1 Species 0.000 claims 4
- 241000700647 Variola virus Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010011793 Cystitis haemorrhagic Diseases 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 201000003740 cowpox Diseases 0.000 claims 2
- 201000002802 hemorrhagic cystitis Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 2
- 208000005871 monkeypox Diseases 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 229940093257 valacyclovir Drugs 0.000 claims 1
- 0 C*I*P(C*[C@@](CN(C=CC(*)=N1)C1=O)COC)(O)=[U] Chemical compound C*I*P(C*[C@@](CN(C=CC(*)=N1)C1=O)COC)(O)=[U] 0.000 description 1
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25670109P | 2009-10-30 | 2009-10-30 | |
| US61/256,701 | 2009-10-30 | ||
| US32699110P | 2010-04-22 | 2010-04-22 | |
| US32698610P | 2010-04-22 | 2010-04-22 | |
| US32698210P | 2010-04-22 | 2010-04-22 | |
| US32698910P | 2010-04-22 | 2010-04-22 | |
| US61/326,986 | 2010-04-22 | ||
| US61/326,982 | 2010-04-22 | ||
| US61/326,991 | 2010-04-22 | ||
| US61/326,989 | 2010-04-22 | ||
| US32747410P | 2010-04-23 | 2010-04-23 | |
| US61/327,474 | 2010-04-23 | ||
| US32791410P | 2010-04-26 | 2010-04-26 | |
| US61/327,914 | 2010-04-26 | ||
| US32849110P | 2010-04-27 | 2010-04-27 | |
| US61/328,491 | 2010-04-27 | ||
| US33062410P | 2010-05-03 | 2010-05-03 | |
| US61/330,624 | 2010-05-03 | ||
| US33170410P | 2010-05-05 | 2010-05-05 | |
| US61/331,704 | 2010-05-05 | ||
| US35543010P | 2010-06-16 | 2010-06-16 | |
| US61/355,430 | 2010-06-16 | ||
| US40507510P | 2010-10-20 | 2010-10-20 | |
| US40508010P | 2010-10-20 | 2010-10-20 | |
| US40507310P | 2010-10-20 | 2010-10-20 | |
| US40508410P | 2010-10-20 | 2010-10-20 | |
| US61/405,080 | 2010-10-20 | ||
| US61/405,075 | 2010-10-20 | ||
| US61/405,084 | 2010-10-20 | ||
| US61/405,073 | 2010-10-20 | ||
| PCT/US2010/054779 WO2011053812A1 (en) | 2009-10-30 | 2010-10-29 | Methods of treating viral associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509433A JP2013509433A (ja) | 2013-03-14 |
| JP2013509433A5 true JP2013509433A5 (enExample) | 2013-12-19 |
Family
ID=43922582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537128A Pending JP2013509433A (ja) | 2009-10-30 | 2010-10-29 | ウイルス関連疾患を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130072458A1 (enExample) |
| EP (1) | EP2493479A4 (enExample) |
| JP (1) | JP2013509433A (enExample) |
| AU (1) | AU2010313273B2 (enExample) |
| CA (1) | CA2779473C (enExample) |
| WO (1) | WO2011053812A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN102670628B (zh) | 2008-01-25 | 2015-11-25 | 奇默里克斯公司 | 治疗病毒感染的方法 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| HUE032860T2 (en) * | 2010-02-12 | 2017-11-28 | Chimerix Inc | A method for treating a virus infection |
| US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
| ES2604137T3 (es) | 2010-08-31 | 2017-03-03 | Chimerix, Inc. | Derivados de éster de fosfonato y métodos de síntesis de los mismos |
| CA2853720A1 (en) * | 2011-10-26 | 2013-05-02 | Chimerix, Inc. | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| CA2857490C (en) | 2011-12-22 | 2020-03-31 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| EP2841162A4 (en) * | 2012-04-27 | 2016-02-24 | Chimerix Inc | METHOD FOR CONTROLLING VIRUS ASSOCIATED ENDORGANIC DAMAGE |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9526729B2 (en) * | 2013-01-29 | 2016-12-27 | Hsiao Lily Yu | Medicament for treating peripheral neuropathies |
| EP3401320B1 (en) | 2013-03-15 | 2020-05-13 | The Regents of the University of California | Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia |
| BR112016010862B1 (pt) | 2013-11-15 | 2022-11-29 | Chimerix, Inc | Formas mórficas de ésteres de hexadeciloxipropilfosfonato, seu método de preparo e composição compreendendo a dita forma mórfica |
| RS63250B1 (sr) | 2014-09-15 | 2022-06-30 | Univ California | Nukleotidni analozi |
| WO2016069630A1 (en) | 2014-10-27 | 2016-05-06 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters bearing at least one deuterium atom |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| WO2017196990A1 (en) * | 2016-05-12 | 2017-11-16 | Contravir Pharmaceuticals, Inc. | Methods of treating hepatitis b infections and related dosage regimes |
| EP3474822B1 (en) | 2016-06-28 | 2025-07-09 | Emergent BioDefense Operations Lansing LLC | Formulations of brincidofovir |
| WO2018156879A1 (en) * | 2017-02-23 | 2018-08-30 | Chimerix, Inc. | Treatment of adenovirus with brincidofovir |
| JP7369143B2 (ja) * | 2018-12-25 | 2023-10-25 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤 |
| US20220184164A1 (en) * | 2019-03-29 | 2022-06-16 | Evonik Operations Gmbh | Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae |
| CN117285565A (zh) * | 2022-06-24 | 2023-12-26 | 润佳（苏州）医药科技有限公司 | 核苷类似物及其医药用途 |
| CA3262284A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| JP4942915B2 (ja) * | 2002-04-26 | 2012-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積 |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US20080020018A1 (en) * | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
| US8642577B2 (en) * | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| EP2125024B1 (en) * | 2007-03-23 | 2013-02-13 | TO-BBB Holding B.V. | Targeted intracellular delivery of antiviral agents |
| EP2155257B1 (en) * | 2007-04-27 | 2016-10-05 | Chimerix, Inc. | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
| EP2462152A4 (en) * | 2009-08-03 | 2013-02-13 | Chimerix Inc | COMPOSITION AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS AND TEMPORED VIRUSES |
| US20110263536A1 (en) * | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
-
2010
- 2010-10-29 CA CA2779473A patent/CA2779473C/en active Active
- 2010-10-29 EP EP10827544.7A patent/EP2493479A4/en not_active Ceased
- 2010-10-29 WO PCT/US2010/054779 patent/WO2011053812A1/en not_active Ceased
- 2010-10-29 AU AU2010313273A patent/AU2010313273B2/en active Active
- 2010-10-29 JP JP2012537128A patent/JP2013509433A/ja active Pending
- 2010-10-29 US US13/504,785 patent/US20130072458A1/en not_active Abandoned
-
2014
- 2014-11-14 US US14/542,295 patent/US20150141375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509433A5 (enExample) | ||
| JP2010525063A5 (enExample) | ||
| RU2015141024A (ru) | Производные эфиров фосфоновых кислот и способы их синтеза | |
| De Clercq et al. | Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines | |
| JP2013231058A5 (enExample) | ||
| Slots | Oral viral infections of adults. | |
| Slifkin et al. | Viral prophylaxis in organ transplant patients | |
| De Clercq | Human viral diseases: what is next for antiviral drug discovery? | |
| De Clercq et al. | Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf | |
| JP2016515128A5 (enExample) | ||
| JP2017520594A5 (enExample) | ||
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2013503882A5 (enExample) | ||
| RU2014116621A (ru) | Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида, обладающий определенным диапазоном распределения частиц по размерам и удельной площади поверхности, для использования в фармацевтических препаратах | |
| JP2014526508A5 (enExample) | ||
| WO2016086153A2 (en) | Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) | |
| CN111265508A (zh) | 双醋瑞因在制备抗病毒药物及治疗病毒感染中的用途 | |
| AU2016271995A1 (en) | Antiviral composition | |
| De Clercq et al. | Unachieved antiviral strategies with acyclic nucleoside phosphonates: Dedicated to the memory of dr. Salvatore “Sam” Joseph Enna | |
| Amarapurkar et al. | Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection | |
| Qadir et al. | Acute HIV Infection: Advances in Mechanisms and Prophylactic Therapeutic Management | |
| WO2020055368A2 (en) | Usage of terpenic coumarin derived molecules in treating viral diseases | |
| Lou et al. | EFFICACY OF ORAL VALGANCICLOVIR IN THE TREATMENT OF CYTOMEGALOVIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS. | |
| Salvador et al. | EFFICACY AND SAFETY OF ORAL VALGANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS INFECTION AFTER A SHORT INDUCTION WITH GANCICLOVIR IV IN SOLID ORGAN TRANSPLANTATION. | |
| Duraffour et al. | Selection and characterization of (S)-1-[3-hydroxy-2-(phosphonomethoxypropyl)-2, 6-diaminopurine [HPMPDAP] resistant Camelpox viruses |